TY - JOUR
T1 - Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration
T2 - a Pragmatic Retrospective Cohort Analysis
AU - Priest, Kelsey C.
AU - Lovejoy, Travis I.
AU - Englander, Honora
AU - Shull, Sarah
AU - McCarty, Dennis
N1 - Funding Information:
This study was funded by the National Institute on Drug Abuse (F30 DA044700, R33 DA035640, UG1 DA015815), the Greenlick Family Scholarship Fund, and the United States Department of Veterans Affairs Health Services Research & Development (IK2HX001516). The funding organizations were not involved in the design of the study, data collection, data analysis, the interpretation of data, or writing of the manuscript. Acknowledgments
Funding Information:
Dr. Lovejoy reports grants from VA Health Services Research & Development during the conduct of the study and grants from National Institutes of Health outside the submitted work. Dr. Priest reports grants from National Institutes of Health and the Greenlick Family Scholarship Fund during the conduct of the study. Drs. Englander, McCarty, and Shull have nothing to disclose.
Publisher Copyright:
© 2020, Society of General Internal Medicine.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background: Hospitalization of patients with opioid use disorder (OUD) is increasing, yet little is known about opioid agonist therapy (OAT: methadone and buprenorphine) administration during admission. Objective: Describe and examine patient- and hospital-level characteristics associated with OAT receipt during hospitalization in the Veterans Health Administration (VHA). Participants: A total of 12,407 unique patients, ≥ 18 years old, with an OUD-related ICD-10 diagnosis within 12 months prior to or during index hospitalization in fiscal year 2017 from 109 VHA hospitals in the continental U.S. Main Measure: OAT received during hospitalization. Key Results: Few admissions received OAT (n = 1914; 15%) and when provided it was most often for withdrawal management (n = 834; 7%). Among patients not on OAT prior to admission who survived hospitalization (n = 10,969), 2.0% (n = 203) were newly initiated on OAT with linkage to care after hospital discharge. Hospitals varied in the frequency of OAT delivery (range, 0 to 43% of qualified admissions). Patients with pre-admission OAT (adjusted odds ratio [AOR] = 15.30; 95% CI [13.2, 17.7]), acute OUD diagnosis (AOR = 2.3; 95% CI [1.99, 2.66]), and male gender (AOR 1.52; 95% CI [1.16, 2.01]) had increased odds of OAT receipt. Patients who received non-OAT opioids (AOR 0.53; 95% CI [0.46, 0.61]) or surgical procedures (AOR 0.75; 95% CI [0.57, 0.99]) had decreased odds of OAT receipt. Large-sized (AOR = 2.0; 95% CI [1.39, 3.00]) and medium-sized (AOR = 1.9; 95% CI [1.33, 2.70]) hospitals were more likely to provide OAT. Conclusions: In a sample of VHA inpatient medical admissions, OAT delivery was infrequent, varied across the health system, and was associated with specific patient and hospital characteristics. Policy and educational interventions should promote hospital-based OAT delivery.
AB - Background: Hospitalization of patients with opioid use disorder (OUD) is increasing, yet little is known about opioid agonist therapy (OAT: methadone and buprenorphine) administration during admission. Objective: Describe and examine patient- and hospital-level characteristics associated with OAT receipt during hospitalization in the Veterans Health Administration (VHA). Participants: A total of 12,407 unique patients, ≥ 18 years old, with an OUD-related ICD-10 diagnosis within 12 months prior to or during index hospitalization in fiscal year 2017 from 109 VHA hospitals in the continental U.S. Main Measure: OAT received during hospitalization. Key Results: Few admissions received OAT (n = 1914; 15%) and when provided it was most often for withdrawal management (n = 834; 7%). Among patients not on OAT prior to admission who survived hospitalization (n = 10,969), 2.0% (n = 203) were newly initiated on OAT with linkage to care after hospital discharge. Hospitals varied in the frequency of OAT delivery (range, 0 to 43% of qualified admissions). Patients with pre-admission OAT (adjusted odds ratio [AOR] = 15.30; 95% CI [13.2, 17.7]), acute OUD diagnosis (AOR = 2.3; 95% CI [1.99, 2.66]), and male gender (AOR 1.52; 95% CI [1.16, 2.01]) had increased odds of OAT receipt. Patients who received non-OAT opioids (AOR 0.53; 95% CI [0.46, 0.61]) or surgical procedures (AOR 0.75; 95% CI [0.57, 0.99]) had decreased odds of OAT receipt. Large-sized (AOR = 2.0; 95% CI [1.39, 3.00]) and medium-sized (AOR = 1.9; 95% CI [1.33, 2.70]) hospitals were more likely to provide OAT. Conclusions: In a sample of VHA inpatient medical admissions, OAT delivery was infrequent, varied across the health system, and was associated with specific patient and hospital characteristics. Policy and educational interventions should promote hospital-based OAT delivery.
KW - buprenorphine
KW - hospital medicine
KW - methadone
KW - opioid agonist therapy
KW - opioid use disorder
UR - http://www.scopus.com/inward/record.url?scp=85083809145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083809145&partnerID=8YFLogxK
U2 - 10.1007/s11606-020-05815-0
DO - 10.1007/s11606-020-05815-0
M3 - Article
C2 - 32291723
AN - SCOPUS:85083809145
SN - 0884-8734
VL - 35
SP - 2365
EP - 2374
JO - Journal of general internal medicine
JF - Journal of general internal medicine
IS - 8
ER -